[Panmyelophthisis induced by the treatment of primary-chronic polyarthritis with gold and D-penicillamine].
D000750:Anemia, Myelophthisic / Q000139:chemically induced* / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006051:Aurothioglucose / Q000009:adverse effects; D001853:Bone Marrow / Q000032:analysis; D001856:Bone Marrow Examination; D002908:Chronic Disease; D005260:Female; D006046:Gold / Q000009:adverse effects* / Q000032:analysis; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000032:analysis; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010396:Penicillamine / Q000009:adverse effects*; D013154:Spleen / Q000032:analysis
D006051:Aurothioglucose; D006046:Gold; D010396:Penicillamine; D008775:Methylprednisolone
Panmyelophthise als Folge einer Behandlung der primär-chronischen Polyarthritis mit Gold und d-Penizillamin.